An update from Synairgen ( (GB:SNG) ) is now available.
Synairgen has announced the adoption of new articles of association following its recent General Meeting, as it transitions to a private limited company. The company has reached an agreement with its majority shareholder, TFG Asset Management UK, to waive rights related to share transfers, allowing shares to remain freely transferable until a future equity fundraise. Additionally, an Asset Match trading facility will be available for two years following the cancellation of its AIM listing, ensuring continued liquidity for shareholders.
More about Synairgen
Synairgen is a UK-based respiratory company focused on developing SNG001, an inhaled interferon beta, as a potential broad-spectrum antiviral treatment for severe viral lung infections. The company aims to address the global need for antiviral therapies, as millions are hospitalized annually due to viral lung infections without approved treatments.
YTD Price Performance: -65.19%
Average Trading Volume: 1,541,882
Technical Sentiment Signal: Buy
Current Market Cap: £10.49M
For an in-depth examination of SNG stock, go to TipRanks’ Stock Analysis page.